{"filing":{"accession_number":"0001104659-26-087725","cik":"0001333141","ticker":"FMCQF","company_name":"Fresenius Medical Care AG","form":"6-K","filing_date":"2026-07-29","report_date":"2026-07-29","primary_document":"tm2621486d1_6k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1333141/000110465926087725/tm2621486d1_6k.htm"},"events":[{"id":21290,"run_id":19193,"accession_number":"0001104659-26-087725","anchor_item_number":"EX-99.1","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"summary":"This press release announces BEACON-US, a comprehensive scientific research initiative evaluating high-volume hemodiafiltration (HVHDF) outcomes in U.S. clinical practice. The disclosure describes an operational and strategic business initiative—expanding access to a therapy across the U.S., building on international evidence, and supporting the company's \"FME Reignite strategy\" for growth and innovation. While the announcement includes clinical data and references to published studies, the core event is the launch of a research program and therapy rollout, which is operational/strategic in nature and does not fit the specific event types (e.g., earnings_release, ma_activity, or exec changes). The initiative is material because it reflects a significant strategic commitment to a key therapeutic area and supports the company's growth strategy.","company_name":"Fresenius Medical Care AG","ticker":"FMCQF","filing_date":"2026-07-29","form":"6-K","submitted_at":null,"items":[{"id":20896,"accession_number":"0001104659-26-087725","item_number":"EX-99.1","item_title":"tm2621486d1_ex99-1.htm","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"This press release announces BEACON-US, a comprehensive scientific research initiative evaluating high-volume hemodiafiltration (HVHDF) outcomes in U.S. clinical practice. The disclosure describes an operational and strategic business initiative—expanding access to a therapy across the U.S., building on international evidence, and supporting the company's \"FME Reignite strategy\" for growth and innovation. While the announcement includes clinical data and references to published studies, the core event is the launch of a research program and therapy rollout, which is operational/strategic in nature and does not fit the specific event types (e.g., earnings_release, ma_activity, or exec changes). The initiative is material because it reflects a significant strategic commitment to a key therapeutic area and supports the company's growth strategy.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-07-29T10:09:45.025146+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":20896,"accession_number":"0001104659-26-087725","item_number":"EX-99.1","item_title":"tm2621486d1_ex99-1.htm","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"This press release announces BEACON-US, a comprehensive scientific research initiative evaluating high-volume hemodiafiltration (HVHDF) outcomes in U.S. clinical practice. The disclosure describes an operational and strategic business initiative—expanding access to a therapy across the U.S., building on international evidence, and supporting the company's \"FME Reignite strategy\" for growth and innovation. While the announcement includes clinical data and references to published studies, the core event is the launch of a research program and therapy rollout, which is operational/strategic in nature and does not fit the specific event types (e.g., earnings_release, ma_activity, or exec changes). The initiative is material because it reflects a significant strategic commitment to a key therapeutic area and supports the company's growth strategy.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-07-29T10:09:45.025146+00:00","company_name":"Fresenius Medical Care AG","ticker":"FMCQF","filing_date":"2026-07-29"}]}